Gene · 56901
COXFA4L2: cytochrome c oxidase hypoxia associated subunit FA4L2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. COXFA4L2: cytochrome c oxidase hypoxia associated subunit FA4L2. Genes, record 56901. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/56901
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9NRX3 | Cytochrome c oxidase hypoxia associated subunit FA4L2 | 87 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents22
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 11073 | Q9NRX3 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2806 | Q9NRX3 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2806 | Q9NRX3 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11073 | Q9NRX3 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 13919 | Q9NRX3 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 13920 | Q9NRX3 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 55060 | Q9NRX3 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 55061 | Q9NRX3 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 158031 | Q9NRX3 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 158032 | Q9NRX3 | Espacenet |
1 to 10 of 22
See all 22 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ME-344 | CHEMBL5314386 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN | CHEMBL1431 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN HYDROCHLORIDE | CHEMBL1703 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| NV-128 | CHEMBL3545135 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
Trials1,218
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604870 | METFORMIN | PHASE2 | ClinicalTrials.gov | |
| NCT07604779 | METFORMIN | ClinicalTrials.gov | ||
| NCT07603505 | METFORMIN | PHASE1 | ClinicalTrials.gov | |
| NCT07589387 | METFORMIN | ClinicalTrials.gov | ||
| NCT07588932 | METFORMIN | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07585396 | METFORMIN | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07582471 | METFORMIN | ClinicalTrials.gov | ||
| NCT07520110 | METFORMIN | PHASE3 | ClinicalTrials.gov | |
| NCT07516821 | METFORMIN | ClinicalTrials.gov | ||
| NCT07513480 | METFORMIN | ClinicalTrials.gov |
1 to 10 of 1,218
See all 1,218 trialsNIH grants262
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | COXFA4L2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 2 | 2025 |
| P30CA177558 | University of Kentucky Markey Cancer Center – Cancer Center Support Grant | 2 | 2025 |
| P30ES019776 | HERCULES: Exposome Research Center | 2 | 2025 |
| P30MH092177 | Comprehensive NeuroHIV Center | 2 | 2025 |
| R35GM118141 | Mitochondrial Biogenesis in Health and Disease | 2 | 2025 |
| I01BX000930 | Oxyntic Atrophy and Novel Gastric Lineages. | 1 | 2025 |
| I01BX002930 | HDAC7-driven metabolic remodeling in renal tumor progression | 1 | 2025 |
| K00CA253718 | Deciphering molecular mechanisms of Epithelial Plasticity | 1 | 2025 |
| K08HL163398 | Molecular regulation of cell fate and progenitor function in the distal human respiratory airways | 1 | 2025 |
1 to 10 of 262Source NIH's project files
See all 262 nih grantsPapers416
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Multi-Gene Myofibroblast Framework Stratifies Prognostic and Immune Landscapes in HCC. | Curr Gene Ther | 2026 | 42393881 | PubTator, text mining | PubMed |
| BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance. | Nat Commun | 2026 | 42393054 | PubTator, text mining | PubMed |
| NDUFA4L2 acts as a mitochondrial checkpoint against ferroptosis in hypoxic clear cell renal cell carcinoma. | Cell Signal | 2026 | 42331208 | PubTator, text mining | PubMed |
| YY1/HIF-1α/NDUFA4L2 signaling axis mediates bisphenol A-induced mitochondrial dysfunction and apoptosis in human ovarian granulosa cells. | Reprod Toxicol | 2026 | 42322997 | PubTator, text mining | PubMed |
| Epigenetics of Genes Displaying High and Preferential Expression in Myoblasts. | Epigenomes | 2026 | 41892369 | PubTator, text mining | PubMed |
| A comprehensive analysis of the circRNA, miRNA, and mRNA networks reveals prognostic biomarkers for gastric cancer. | Z Gastroenterol | 2026 | 41862194 | PubTator, text mining | PubMed |
| Targeting regulated cell death pathways in lung cancer: mechanisms, therapeutic strategies, and clinical translation. | Front Immunol | 2026 | 41789093 | PubTator, text mining | PubMed |
| NDUFA4L2 regulates the progression and chemotherapy sensitivity of HNSCC by inhibiting PANoptosis. | NPJ Precis Oncol | 2026 | 41787028 | PubTator, text mining | PubMed |
| Cornus officinalis Fruit Extract as an AMPK-Associated Mitochondrial Bioenergetic Modulator in Skin Aging Models. | Biomedicines | 2026 | 41751302 | PubTator, text mining | PubMed |
| Bioinformatics Analysis of Genes Associated with Autophagy and Metabolic Reprogramming in Atrial Fibrillation. | J Cardiovasc Dev Dis | 2026 | 41745330 | PubTator, text mining | PubMed |
1 to 10 of 416
See all 416 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/56901
GET https://conductscience.org/api/genes/v1/56901/patents?page=2